Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2014

Study Completion Date

October 31, 2015

Conditions
Breast CancerHER2-negative Breast Cancer
Interventions
DRUG

Paclitaxel

80 mg/m2 IV over 60 minutes weekly for 12 weeks

DRUG

Eribulin

1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles

DRUG

Doxorubicin

60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles

DRUG

Cyclophosphamide

600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles

Trial Locations (20)

15212

Allegheny General Hospital/Allegheny-Singer Research Institute, Pittsburgh

NSABP Foundation, Inc., Pittsburgh

19141

Albert Einstein Medical Center, Philadelphia

26506

Mary Babb Randolph Cancer Center at West Virginia University Hospitals, Morgantown

27157

Wake Forest University Health Sciences, Winston-Salem

28203

Carolinas Medical Center/Levine Cancer Center, Charlotte

29401

Roper Hospital, Charleston

29615

Cancer Centers of the Carolinas, Greenville

31404

Memorial Health University Medical Center, Savannah

31703

Phoebe Putney Memorial Hospital, Albany

33140

CCOP - Mount Sinai Medical Center, Miami Beach

48202

Henry Ford Health System, Detroit

49007

West Michigan Cancer Center, Kalamazoo

79410

Joe Arrington Cancer Research & Treatment Center, Lubbock

80222

CCOP, Colorado Cancer Research Program, Inc., Denver

48075-9975

Providence Hospital - Southfield, Southfield

08901

Cancer Institute of New Jersey, New Brunswick

15232-1305

University of Pittsburgh, Pittsburgh

H2W-1T8

Centre Hospitalier de l'Universite de Montreal, Montreal

H3G 1A4

Montreal General Hospital, Montreal

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

NSABP Foundation Inc

NETWORK

NCT01705691 - Comparison of Neoadjuvant Chemotherapy With Weekly Paclitaxel or Eribulin Followed by A/C in Women With Locally Advanced HER2-Negative Breast Cancer | Biotech Hunter | Biotech Hunter